Related Experiment Videos
Corticosteroids and chronic lung disease in extremely immature infants: a dilemma
G Moriette1, Y Mikaeloff, P H Jarreau
1Service de Médecine Néconatale de Port-Royal, UFR Cochin Port-Royal, Université René Descartes, Paris, France.
Insights
The optimal timing for dexamethasone treatment in extremely premature infants remains unclear. Early treatment risks outweigh benefits, while later treatment may be more appropriate for preventing chronic lung disease (CLD).
Area of Science:
- Neonatalogy
- Pediatric Pharmacology
- Respiratory Medicine
Background:
- Dexamethasone is used to prevent chronic lung disease (CLD) in extremely immature infants.
- The optimal timing and regimen for dexamethasone administration are debated.
- Potential risks include impaired growth and neurodevelopmental outcomes.
Purpose of the Study:
- To evaluate the balance of benefits and risks of dexamethasone in extremely immature infants.
- To determine the most appropriate treatment window for dexamethasone to prevent CLD.
- To compare the efficacy and safety of different dexamethasone dosing schedules.
Main Methods:
- Review of existing literature on dexamethasone use in extremely premature infants.
- Analysis of treatment timing (early vs. later) and its impact on CLD incidence.
- Assessment of short-term benefits (e.g., reduced ventilation duration) and potential long-term risks.
Main Results:
- Early dexamethasone treatment (before day 7) may overtreat infants who would not develop CLD.
- Treatment initiated between days 7-14 may target higher-risk infants.
- Both 7-day courses and pulse therapy show effectiveness, but direct comparisons are lacking.
Conclusions:
- The optimal timing for dexamethasone remains uncertain, with potential risks of early treatment.
- Later treatment initiation (days 7-14) may be more targeted for CLD prevention.
- Further research is needed to compare different dexamethasone regimens and their long-term effects on growth and development.
Abstract:
What is the balance of benefits and risks of dexamethasone in extremely immature infants? The answer remains unclear. We feel that the risks of "early" treatment outweigh the benefits, because many infants who would not develop CLD will be treated. Treatment between day 7 and day 14 seems more appropriate to us, as it focuses on infants with a high risk of developing CLD. However, the lungs may be already somewhat damaged when starting treatment, whose expected benefit is a shortened duration of mechanical ventilation and a decreased incidence of CLD. The risks for growth and brain development are not clearly assessed. Both 7-day courses and pulse therapy are effective, but no comparison of these 2 schedules has been published. We therefore do not know whether pulse therapy provides the same benefits as 7-day courses with fewer risks for growth or cardiomyopathy.